Harding, J. J., Piha-Paul, S. A., Shah, R. H., Murphy, J. J., Cleary, J. M., Shapiro, G. I., . . . Abou-Alfa, G. K. (2023). Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature communications, 14(1), 630-12. https://doi.org/10.1038/s41467-023-36399-y
Citace podle Chicago (17th ed.)Harding, James J., et al. "Antitumour Activity of Neratinib in Patients with HER2-mutant Advanced Biliary Tract Cancers." Nature Communications 14, no. 1 (2023): 630-12. https://doi.org/10.1038/s41467-023-36399-y.
Citace podle MLA (9th ed.)Harding, James J., et al. "Antitumour Activity of Neratinib in Patients with HER2-mutant Advanced Biliary Tract Cancers." Nature Communications, vol. 14, no. 1, 2023, pp. 630-12, https://doi.org/10.1038/s41467-023-36399-y.